The small molecule BI-2852 induces a nonfunctional dimer of KRAS
- PMID: 32047043
- PMCID: PMC7035607
- DOI: 10.1073/pnas.1918164117
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Conflict of interest statement
Competing interest statement: F.M. is a consultant for the following companies: AduroBiotech; Amgen; Daiichi, Ltd.; PellePharm; Pfizer, Inc.; PMV Pharma; and Portola Pharmaceuticals. F.M. is Scientific Director of the National Cancer Institute RAS Initiative at Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. F.M. is a consultant for and cofounder of the following companies: Avidity, BridgeBio, KGen, and Quartz.
Figures
Comment in
-
Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3365-3367. doi: 10.1073/pnas.1921236117. Epub 2020 Feb 11. Proc Natl Acad Sci U S A. 2020. PMID: 32047042 Free PMC article. No abstract available.
Comment on
-
Drugging an undruggable pocket on KRAS.Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829. doi: 10.1073/pnas.1904529116. Epub 2019 Jul 22. Proc Natl Acad Sci U S A. 2019. PMID: 31332011 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
